trial

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCTId NCT00845026
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 261 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2010-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
261 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2009-03
Primary completion
2010-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PomaglumetadAripiprazoleOlanzapineRisperidone

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

23 total
Escondido, United StatesGarden Grove, United StatesWashington D.C., United StatesChicago, United StatesHoffman Estates, United StatesIndianapolis, United StatesLake Charles, United StatesWillingboro, United StatesAmityville, United StatesOklahoma City, United StatesDeSoto, United StatesJena, Germany

Linked catalysts

1
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment — primary completion2010-05

Facts & assertions

4 sourced
Enrollment
261
Phase
PHASE2
Primary Completion Date
2010-05
Status
COMPLETED
relationships
The graph out of here
drug
Pomaglumetad
drug
Aripiprazole
drug
Olanzapine
drug
Risperidone
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person